Patents Assigned to Evotec AG
-
Patent number: 9759659Abstract: A method for identifying the impact on data, such as experimental data, of interfering effects, such as unwanted auto-fluorescence, fluorescence quenching, and fluorescent-sample deterioration, whether or not the data fulfill certain criteria with respect to a threshold indicative of the interfering effects.Type: GrantFiled: March 10, 2011Date of Patent: September 12, 2017Assignee: EVOTEC AGInventors: Christian Eggeling, Kaupo Palo, Nicolas Fay, Maciej Hoffman-Wecker, Pierre Ilouga
-
Patent number: 9133122Abstract: Compounds are provided according to formula 1: where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.Type: GrantFiled: July 9, 2014Date of Patent: September 15, 2015Assignee: EVOTEC AGInventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
-
Patent number: 8946439Abstract: Compounds are provided according to formula 1: where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.Type: GrantFiled: February 27, 2009Date of Patent: February 3, 2015Assignee: Evotec AGInventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
-
Patent number: 8912176Abstract: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: GrantFiled: January 29, 2010Date of Patent: December 16, 2014Assignee: Evotec AGInventors: Adam James Davenport, David James Hallett, Christopher Charles Stimson
-
Patent number: 8859545Abstract: Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds are disclosed that have formula 1: where A, B, L, N, R1, R3, R4?, Y and Z are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, respiratory conditions, and others.Type: GrantFiled: March 1, 2010Date of Patent: October 14, 2014Assignee: Evotec AGInventors: Michael G. Kelly, John Kincaid, Carl J. Kaub
-
Patent number: 8691804Abstract: The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. These compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: GrantFiled: May 5, 2009Date of Patent: April 8, 2014Assignee: Evotec AGInventors: Adam James Davenport, David James Hallett, Massimo Corsi
-
Publication number: 20140073627Abstract: The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: ApplicationFiled: November 7, 2013Publication date: March 13, 2014Applicant: EVOTEC AGInventors: James MADDEN, David James HALLETT, Alastair PARKES, Ali RAOOF, Xiaolu WANG
-
Patent number: 8653091Abstract: Fused heterocyclic compounds are provided according to formula 1a or 1b: where R1, R2, and R3 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.Type: GrantFiled: March 31, 2008Date of Patent: February 18, 2014Assignee: Evotec AGInventors: Zhi-Liang Wei, John Kincaid, Michael G. Kelly, Donogh John Roger O'Mahony, Carl Kaub
-
Patent number: 8623859Abstract: The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: GrantFiled: August 10, 2009Date of Patent: January 7, 2014Assignee: Evotec AGInventors: James Madden, David James Hallett, Alastair Parkes, Ali Raoof, Xiaolu Wang
-
Patent number: 8580577Abstract: The present invention relates to a method for detecting an analyte in a sample comprising the steps of providing detection probes being labeled with a first reporter, which detection probes are capable of binding to the analyte, providing a solid support, providing capture probes being bound or capable of binding to the solid support, which capture probes are capable of binding to the analyte, thus concentrating the analyte on the solid support, contacting the sample with the detection probes, the solid support and the capture probes, and detecting the detection probes, wherein the detection of detection probes is conducted in the presence of quenching probes binding to surplus detection probes not being bound to the analyte and thereby quenching at least partially an emission of the first reporter of said surplus detection probes and/or the solid support is labeled with a second reporter different from the first reporter, imaging the sample at an emission wavelength of the second reporter, generating a mType: GrantFiled: May 10, 2010Date of Patent: November 12, 2013Assignee: Evotec AGInventors: Silke Hinnah, Dagmar Lambrü, Sonja Dröge, Stefan Jäger, Karsten Gall, Werner Stürmer, Michaela Schäfer
-
Patent number: 8574861Abstract: 1. Use of (v) a gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (vi) a transcription product of the gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (vii) a translation product of the gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (viii) a fragment, or derivative, or variant of (i) to (iii). for identifying or for testing agents for the treatment and/or prevention of neurodegenerative diseases.Type: GrantFiled: October 24, 2008Date of Patent: November 5, 2013Assignee: Evotec AGInventor: Heinz Von Der Kammer
-
Patent number: 8163901Abstract: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.Type: GrantFiled: January 9, 2009Date of Patent: April 24, 2012Assignee: Evotec AGInventors: Matthew Duncton, Donogh John Roger O'Mahony, Matthew Cox, Maria De Los Angeles Estiarte-Martinez
-
Patent number: 8153651Abstract: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.Type: GrantFiled: November 13, 2008Date of Patent: April 10, 2012Assignee: Evotec AGInventors: Matthew Cox, Donogh John Roger O'Mahony, Maria De Los Angeles Estiarte-Martinez, Tadashi Kawashima, Satoshi Nagayama, Yuji Shishido, Hirotaka Tanaka, Matthew Alexander James Duncton, Andrew Antony Calabrese
-
Publication number: 20120040952Abstract: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: ApplicationFiled: January 29, 2010Publication date: February 16, 2012Applicant: EVOTEC AGInventors: Adam James Davenport, David James Hallett, Christopher Charles Stimson
-
Patent number: 8076345Abstract: Fused heterocyclic compounds are provided according to formula 1: where R1, R2, R3, and m are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.Type: GrantFiled: March 31, 2008Date of Patent: December 13, 2011Assignee: Evotec AGInventors: Zhi-Liang Wei, Donogh John Roger O'Mahony, Matthew Duncton, John Kincaid, Michael G. Kelly, Zhan Wang
-
Publication number: 20110201589Abstract: The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: ApplicationFiled: August 10, 2009Publication date: August 18, 2011Applicant: EVOTEC AGInventors: James Madden, David James Hallett, Alastair Parkes, Ali Raoof, Xialou Wang
-
Publication number: 20110105459Abstract: The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: ApplicationFiled: May 5, 2009Publication date: May 5, 2011Applicant: EVOTEC AGInventors: Adam James Davenport, David James Hallett, Massimo Corsi
-
Publication number: 20110046130Abstract: The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: ApplicationFiled: March 27, 2009Publication date: February 24, 2011Applicant: Evotec AGInventors: Adam James Davenport, David James Hallett, Frédéric Marlin, Mark Gemkow
-
Patent number: 7867707Abstract: The present invention relates to a method for detecting analytes in a sample comprising the steps of providing a solid support, providing capture probes being bound or capable of binding to the solid support, which capture probes are also capable of binding to the analytes, thus concentrating the analytes on the solid support, providing detection probes which are capable of binding to the analytes, contacting the sample with the detection probes, the solid support and the capture probes, and detecting through use of confocal observation the analytes which are bound to the detection probes.Type: GrantFiled: June 11, 2004Date of Patent: January 11, 2011Assignee: Evotec AGInventors: Silke Christine Hinnah, Dagmar Lambrü, Sonja Dröge, Stefan Jäger, Karsten Gall, Werner Stürmer, Michaela Schäfer
-
Patent number: RE44555Abstract: A method for analyzing chemical and/or biological samples comprises the production of a particle image (42) of at least one particle included in the sample. Subsequently, a particle surface (10) of the at least one particle included in the particle image (42) is divided into particle zones (14,18). According to the invention, zone-dependent particle data are subsequently acquired in different states (z1, z2, z3), which then can be evaluated.Type: GrantFiled: August 4, 2008Date of Patent: October 22, 2013Assignee: Evotec AGInventors: Achim Kirsch, Olavi Ollikainen